Side-by-side · Research reference
5-Amino-1MQvsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BHuman-MechanisticDraft12/39 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
5-Amino-1MQ
Semax
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
—
—
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Semax
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
200–600 mcg / dose intranasalKaplan 2017
Frequency
Once daily, fasted
2–3× per day during cognitive demand
Lower / starter dose
50 mg / day
100 mcg / dose
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Human-mechanistic + Russian clinicalKaplan 2017
Duration
8–12 weeks per cycle
10–14 day cycles, repeated PRN
Form
Oral capsule
—
Timing
Morning fasted preferred
Morning + early afternoon
Half-life
Hours (estimated; no human PK published)
Short plasma; CNS effect lasts ~3–6 hr
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
04Side Effects & Safety
Parameter
5-Amino-1MQ
Semax
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
Limited Western RCT data
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Avoid
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
5-Amino-1MQ
Semax
1. Form
Oral capsule. No injection.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Administration
Take with water, fasted preferred.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
Morning fasted.
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
Room temp ≤25 °C, dry place.
Refrigerate after reconstitution; light-protected.
5. Caveat
Monitor B-vitamin status with chronic use.
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
5-Amino-1MQ
— no documented stacks
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation